Cash, cash equivalents and marketable securities were $555.3M as of September 30, compared to $754.4M as of December 31, 2024.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XENE:
- XENE Upcoming Earnings Report: What to Expect?
- Xenon Pharmaceuticals’ Phase 3 Study on Azetukalner: A Potential Game-Changer for Major Depressive Disorder
- Xenon Pharmaceuticals’ Phase 3 Study on Azetukalner: A Potential Game-Changer in Depression Treatment
- Xenon Pharmaceuticals’ XEN1101 Trial: A Promising Step in Seizure Treatment
- Xenon Pharmaceuticals Advances Bipolar Depression Treatment with Azetukalner Study